Clarendon Fund Managers | AMPLY DISCOVERY EXPLAINS HOW ITS AI TECHNOLOGY CAN IDENTIFY NOVEL BIOLGICAL DRUG CANDITATES
2508
post-template-default,single,single-post,postid-2508,single-format-standard,qode-listing-1.0.1,qode-social-login-1.0,qode-news-1.0,qode-quick-links-1.0,qode-restaurant-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-theme-ver-12.1,qode-theme-bridge,bridge,wpb-js-composer js-comp-ver-5.4.2,vc_responsive
 

AMPLY DISCOVERY EXPLAINS HOW ITS AI TECHNOLOGY CAN IDENTIFY NOVEL BIOLGICAL DRUG CANDITATES

08 Sep AMPLY DISCOVERY EXPLAINS HOW ITS AI TECHNOLOGY CAN IDENTIFY NOVEL BIOLGICAL DRUG CANDITATES

Posted at 16:24h in Uncategorised by

CEO, Ben Thomas, and CCO, Dermot Tierney, joined Moira Gunn from BioTech Nation to discuss exactly why the company was formed and how, with the assistance of AI and machine learning, it’s technology can identify novel biological drug and nutraceutical candidates

Click here to listen.

Podcast taken from: https://www.biotechnation.com/episodes/why-do-ai-one-way-when-you-can-do-it-25-dr-ben-thomas-and-dermot-tierny-ceo-cco-amply-discovery

Print page